TEV-50717
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions
Cerebral Palsy, DyskineticTourette Syndrome
Phase 2
Phase 3
Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
TerminatedNCT03567291
Start: 2018-05-25End: 2020-05-15Updated: 2021-11-09
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
CompletedNCT03571256
Start: 2018-05-31End: 2019-12-09Updated: 2021-11-09
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
CompletedNCT03813238
Start: 2019-08-06End: 2022-07-21Updated: 2023-09-08
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
TerminatedNCT04200352
Start: 2020-02-04End: 2023-02-14Updated: 2024-04-22